On May 28, 2025, Candel Therapeutics, Inc. announced that the FDA awarded Regenerative Medicine Advanced Therapy designation to their lead candidate, CAN-2409, for treating newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease.